Understand the source comparison
Top Selling Peptides May 2026: Research Application Comparison
This table compares the primary research applications, mechanisms of action, and distinguishing characteristics of the top selling peptides may 2026 based on current laboratory demand and published mechanistic data. Tirzepatide Metabolic dysfunction, insulin r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the primary research applications, mechanisms of action, and distinguishing characteristics of the top selling peptides may 2026 based on current laboratory demand and published mechanistic data.
- Tirzepatide
- Metabolic dysfunction, insulin resistance, obesity models
- Dual GIP/GLP-1 receptor agonist. Enhances insulin sensitivity and slows gastric emptying
- First FDA-approved dual agonist; 20.9% weight reduction in SURMOUNT-1 trial
- Gold standard for multi-pathway metabolic research in 2026
- Retatrutide
- Severe obesity models, hepatic steatosis, thermogenesis
- Triple GLP-1/GIP/glucagon receptor agonist. Adds hepatic fat oxidation and thermogenic energy expenditure
- Highest weight reduction (24%) in any peptide trial to date
- Preferred for studies requiring glucagon-driven lipolysis
- Survodutide
- Visceral adiposity, NAFLD, body composition
- Dual GLP-1/glucagon receptor agonist. Preferential visceral fat reduction
- MRI-confirmed preferential reduction in hepatic and abdominal fat versus subcutaneous
- Best choice for visceral obesity and liver fat research
- Dihexa
- Neuroplasticity, synaptogenesis, TBI models
- HGF/c-Met pathway activation. Increases hippocampal synapse density by >40%
- 7–10× more potent than BDNF at promoting synaptic growth
- Leading structural neuroplasticity compound in current use
- Cerebrolysin
- Stroke recovery, neurodegenerative disease, TBI rehabilitation
- Multi-factor neurotrophic support (BDNF, GDNF, NGF)
- Strongest clinical evidence base. Over 150 published trials
- Most clinically validated neuroprotective peptide available
- Epithalon
- Cellular aging models, telomere biology, senescence delay
- Telomerase activation. Increases telomere length in somatic cells
- 33% telomere length increase in human cells (St. Petersburg Institute)
- Primary telomerase-focused compound in longevity research
- FOXO4 DRI
- Senescent cell clearance, tissue regeneration, age-related fibrosis
- Disrupts FOXO4-p53 interaction. Selectively induces apoptosis in senescent cells
- Demonstrated reversal of age-related phenotypes in mice (Cell, 2017)
- Leading senolytic peptide with published in vivo efficacy
- BPC 157
- Tissue repair, angiogenesis, GI protection
- Angiogenic. Promotes VEGF expression and endothelial migration
- Effective across multiple tissue types (tendon, muscle, gastric mucosa)
- Most versatile tissue repair peptide in research use